In the premarket trading session, Aptorum Group Limited (APM) stock had plunged by -3.57% to trade at the price of $2.70 at the last check. APM previously closed the session at $2.80. The APM stock volume traded 41.59 million shares. In the past year up to date, APM stock have shed -11.39% however in the past week, they have moved up by 14.75%. In the past three and six months, the APM stock had shed-23.29% and added 16.18% respectively. Furthermore, Aptorum Group Limited (APM) is currently valued in the market at $95.28 million and has 32.31 million outstanding shares.
Here’s what you need to know about Aptorum Group Limited (APM)
Aptorum Group Limited is a pharmaceutical company that specifically focuses on providing therapeutics and treatments for diseases that have unmet requirements in the medical fields and platforms. Aptorum was established in 2010 and is based in London, United Kingdom. The company specializes in the design, manufacturing, and marketing of the treatments of infectious diseases and cancers. APM stock does this uniquely through its investigative platforms for its therapeutic candidates which allows for it to discover innovative metabolic disease treatments through screening of existing drug molecules and microbiome-based researches. Apart from metabolic disorders and treatments the company is looking to expand its portfolio of treatments and therapeutics for gastroenterology, neurology, women’s health, and other disease areas. This helps APM stock to cover a broader spectrum of the therapeutics and treatments segment of the pharmaceutical market. This is proved by the company’s focus on diversification through projects that focus on surgical robotics and natural supplement for menopause and menstrual cycle-related effects.
Aptorum has announced progress and positive results in both ASL-4 and SACT-1’s study
Two of the Aptorum’sprojects are showing progress and positive results in their study. The company announced on 24th May 2021, that the ALS-4’s clinical trial has shown positive results by indicating no serious adverse effects in its report. The clinical trial is in phase 1 under which female and male healthy subjects are administered two initial cohorts of single-dose ascending dose (SAD).
The second project that has shown positive results is for SACT-1’s ongoing preparation for pre-IND. The company reports that the pre-IND meeting that was to be given with the US FDA has been completed.
What are the details and next step in the trials?
The ALS-4 trial’s two cohorts were Cohort A of 25mg and Cohort B of 50 mg. There were 8 subjects for this trial among which 2 had received the placebo. Additionally, the electrocardiogram, clinical laboratory tests, vital signs, and other examinations showed no clinical changes relevant to the regular baseline. ALS-4 is used for the targeting of Staphylococcus Aureus including Methicillin-Resistant Staphylococcus Aureus. The next step in the phase I trial is to go for the remaining 4 of the total 6 cohorts for SAD and 3 cohorts for MAD. Further studies of the cohort are planned now with the cohort 100 mg being initiated
The SACT-1 is supported in its discovery through the company’s proprietary SMART-ACT® platform. SACT-1 is the company’s current project for cancer treatment and elimination of neuroblastoma. SACT-1 is capable of enhanced DNA damage and tumor cell death according to internal studies. The guidance from the US FDA has opened up a path for SACT-1 trial and opened an IND to commence clinical studies in quarter 3 of 2021.